Literature DB >> 23756634

Effects of Schedule I drug laws on neuroscience research and treatment innovation.

David J Nutt1, Leslie A King, David E Nichols.   

Abstract

Many psychoactive drugs are used recreationally, particularly by young people. This use and its perceived dangers have led to many different classes of drugs being banned under national laws and international conventions. Indeed, the possession of cannabis, 3,4-methylenedioxy-N-methylamphetamine (MDMA; also known as ecstasy) and psychedelics is stringently regulated. An important and unfortunate outcome of the controls placed on these and other psychoactive drugs is that they make research into their mechanisms of action and potential therapeutic uses - for example, in depression and post-traumatic stress disorder - difficult and in many cases almost impossible.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23756634     DOI: 10.1038/nrn3530

Source DB:  PubMed          Journal:  Nat Rev Neurosci        ISSN: 1471-003X            Impact factor:   34.870


  50 in total

1.  Functional connectivity measures after psilocybin inform a novel hypothesis of early psychosis.

Authors:  Robin L Carhart-Harris; Robert Leech; David Erritzoe; Tim M Williams; James M Stone; John Evans; David J Sharp; Amanda Feilding; Richard G Wise; David J Nutt
Journal:  Schizophr Bull       Date:  2012-10-08       Impact factor: 9.306

2.  Psychiatry, the pharmaceutical industry, and the road to better therapeutics.

Authors:  H Christian Fibiger
Journal:  Schizophr Bull       Date:  2012-06       Impact factor: 9.306

Review 3.  MDMA (Ecstasy).

Authors:  Rif S El-Mallakh; Henry David Abraham
Journal:  Ann Clin Psychiatry       Date:  2007 Jan-Mar       Impact factor: 1.567

4.  Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.

Authors:  Amir Englund; Paul D Morrison; Judith Nottage; Dominic Hague; Fergus Kane; Stefania Bonaccorso; James M Stone; Avi Reichenberg; Rudolf Brenneisen; David Holt; Amanda Feilding; Lucy Walker; Robin M Murray; Shitij Kapur
Journal:  J Psychopharmacol       Date:  2012-10-05       Impact factor: 4.153

Review 5.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

Review 6.  Hallucinogens.

Authors:  David E Nichols
Journal:  Pharmacol Ther       Date:  2004-02       Impact factor: 12.310

Review 7.  A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response.

Authors:  A Richard Green; Esther O'shea; M Isabel Colado
Journal:  Eur J Pharmacol       Date:  2004-10-01       Impact factor: 4.432

8.  A method of conducting therapeutic sessions with MDMA.

Authors:  G R Greer; R Tolbert
Journal:  J Psychoactive Drugs       Date:  1998 Oct-Dec

9.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

10.  Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

Authors:  John Peter Zajicek; Jeremy C Hobart; Anita Slade; David Barnes; Paul G Mattison
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-07-12       Impact factor: 10.154

View more
  61 in total

1.  Abuse of New Psychoactive Substances: Threats and Solutions.

Authors:  Michael H Baumann; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2015-08-25       Impact factor: 7.853

Review 2.  Psychedelic medicine: a re-emerging therapeutic paradigm.

Authors:  Kenneth W Tupper; Evan Wood; Richard Yensen; Matthew W Johnson
Journal:  CMAJ       Date:  2015-09-08       Impact factor: 8.262

3.  Controlled substances and innovation of biomedicine: a preclinical perspective.

Authors:  Adam Michael Stewart; Allan V Kalueff
Journal:  Nat Rev Neurosci       Date:  2013-10-23       Impact factor: 34.870

4.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

5.  Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science".

Authors:  David Nutt
Journal:  EMBO Rep       Date:  2014-02-14       Impact factor: 8.807

Review 6.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

Review 7.  Lysergic acid diethylamide: a drug of 'use'?

Authors:  Saibal Das; Preeti Barnwal; Anand Ramasamy; Sumalya Sen; Somnath Mondal
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-23

Review 8.  Zebrafish as an emerging model for studying complex brain disorders.

Authors:  Allan V Kalueff; Adam Michael Stewart; Robert Gerlai
Journal:  Trends Pharmacol Sci       Date:  2014-01-09       Impact factor: 14.819

9.  Psilocybin, psychological distress, and suicidality.

Authors:  Peter S Hendricks; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-09       Impact factor: 4.153

Review 10.  The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.

Authors:  Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield
Journal:  Neuropharmacology       Date:  2018-06-05       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.